Adecatumumab (MT201) is a recombinant human monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM – CD326).Adecatumumab has been used in clinical studies of treatment in prostate and breast cancers.
This page contains content from the copyrighted Wikipedia article "Adecatumumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.